Co-Diagnostics, Inc. (CODX)

Market Cap	35.64M
Revenue (ttm)	6.81M
Net Income (ttm)	-35.33M
Shares Out	31.26M
EPS (ttm)	-1.20
PE Ratio	n/a
Forward PE	16.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,356
Open	1.130
Previous Close	1.140
Day's Range	1.120 - 1.170
52-Week Range	0.975 - 1.890
Beta	-0.68
Analysts	Hold
Price Target	2.50 (+117.39%)
Earnings Date	May 9, 2024

About CODX

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addi...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 12, 2017
• Employees: 155
• Stock Exchange: NASDAQ
• Ticker Symbol: CODX

Financial Performance

In 2023, Co-Diagnostics's revenue was $6.81 million, a decrease of -80.09% compared to the previous year's $34.22 million. Losses were -$35.33 million, 148.2% more than in 2022.

Analyst Forecast

According to one analyst, the rating for CODX stock is "Hold" and the 12-month stock price forecast is $2.5.

Price Target

$2.5

(117.39% upside)

Analyst Consensus: Hold